DERL1 and amyotrophic lateral sclerosis: Although we cannot exclude the possibility that #56 analogs inhibit the interaction of SOD1mut through the DBR not only with Derlin-1 but also with other proteins, the SOD1-Derlin-1 interaction is the most likely and promising target for ALS treatment.